A proven team of industry-defining executives, physician-scientists, and strategists with a demonstrated record of building, scaling, and commercializing breakthrough therapies across global healthcare markets.
Steve Carlson — Chief Executive Officer
Steve Carlson is a pioneering leader in the development and commercialization of Botox.® As General Manager of the Botox division at Allergan, he helped transform a $3.5M investment into a $7.5B global therapeutic and aesthetic franchise, including the breakthrough approval for Chronic Migraine.
He has led more than 50 clinical trials with over 50,000 patients, contributed to eight FDA product approvals, launched more than 25 products, guided six healthcare startups, and raised over $300M in capital. His role in the Obagi IPO helped drive a market cap increase from $220M to $440M.
L. Andrew Koman, MD — Chief Science/Medical Officer
Dr. L. Andrew Koman is a globally recognized clinical pioneer with nearly four decades of experience in Botulinum Toxin research and treatment. He performed the world’s first Botulinum Toxin procedures for cerebral palsy and has been honored twice by the American Academy of Orthopaedic Surgeons for landmark contributions.
He has held major leadership positions across Wake Forest University and Atrium Health, secured NIH funding exceeding $2M, published over 250 peer-reviewed papers, and completed multiple FDA labeling trials. His innovations include patented techniques in dose optimization and anatomical targeting.
David L. Reicher — Chairman and Chief Strategy Officer
Dr. David Reicher is an accomplished executive, physician, and strategist with a record of building and scaling healthcare enterprises. As co-founder and CEO/President of Data Trace, he grew the organization into an eight-entity platform spanning CRO operations, medical devices, medical malpractice insurance, and scientific publishing.
He secured FDA 510(k) and PMA approvals for the Hintermann Ankle Replacement Systems and maintains one of the industry’s most extensive orthopaedic networks, including leadership of 14 orthopaedic specialty associations. He has executed over $850M in corporate and advisory M&A transactions.
Matthew Jacobson — Chief Legal Officer, General Counsel
Matthew Jacobson, is a seasoned executive and legal strategist with more than 25 years of experience leading high-impact transactions and complex strategic legal initiatives across both top-tier law firms and in-house roles. A global transactional leader, he has advised companies and investment funds of all sizes across multiple industries and jurisdictions worldwide. Mr. Jacobson is widely recognized as a leading authority in mergers and acquisitions, having been named by Legal 500 US for excellence in mid-market and large-cap M&A transactions—including deals exceeding $1 billion—as well as commercial and technology transactions. He has also been recognized as a “Stand-Out Lawyer” by Thomson Reuters. Mr. Jacobson earned his Juris Doctor from UC Hastings College of the Law and his Bachelor of Arts from Stanford University.
